World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 3
Page: 1078-1094

A REVIEW ON "ADVANCEMENTS IN ANTIBIOTIC AND IMMUNOTHERAPY APPROACHES FOR THE MANAGEMENT OF LYME DISEASE"

Rohit Kumar[1], Abhishek Bhardwaj[2]*, Krati[3], Dr. Esha Vatsa[3] and Dr. Amandeep Singh[4]

[1]Student, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

[2]Assistant Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

[3]Assistant Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

[4]Principal & Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

Article Received: 06 May 2025 // Article Revised: 26 May 2025 // Article Accepted: 18 June 2025

***Corresponding Author: Abhishek Bhardwaj**
Assistant Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun
DOI: https://doi.org/10.5281/zenodo.15774077

How to cite this Article: Rohit Kumar, Abhishek Bhardwaj, Krati, Dr. Esha Vatsa and Dr. Amandeep Singh (2025) A RESEARCH ON FORMULATION AND EVALUTION OF CASSIA BIFLORA VATI. World Journal of Pharmaceutical Science and Research, 4(3), 1078-1094. https://doi.org/10.5281/zenodo.15774077

ABSTRACT

Lyme borreliosis, also known as Lyme disease, is an infection caused by spirochetes from the *Borrelia burgdorferi* sensu lato species complex, which are transmitted through tick bites. The primary clinical symptom is erythema migrans, a characteristic circular rash that typically resolves on its own without the need for antibiotics. However, if left untreated, the bacteria can disseminate to other parts of the body, leading to more serious complications that may affect the skin, nervous system, joints, or heart. Between May and September, when ticks are in their nymphal stage and most active in spreading the infection, Lyme disease is most frequently contracted.**.** Erythema migrans, the main clinical symptom of Lyme disease, is a characteristic rash that usually goes away on its Abstraction In the UK, ticks are endemic for transporting the bacterium Borrelia, which causes Lyme disease. The incidence of Lyme disease is gradually growing along with the quantity of ticks. Nurses must be capable of diagnosing and treating patients who have been bitten by a tick or who may have Lyme disease. A comprehensive and well-informed strategy will improve patient satisfaction and care quality while offering chances for illness prevention and successful treatment.own without the need for antibiotics.

KEYWORD: Lyme Borreliosis, Spirochetes, Erythema Migrans.

INTRODUCTION

The bacterium Borrelia burgdorferi is the cause of Lyme disease, also referred to as Lyme borreliosis.[1] In Europe and Asia, B. burgdorferi has been the main cause of Lyme disease since its discovery in 1976. Nonetheless, slightly different clinical symptoms are also produced by other borrelial genospecies, including Borrelia afzelii and Borrelia garini. Generally speaking, B. burgdorferi is the most genospecies that causes arthritis, B. garini produces the most common neurological symptoms, and B. afzeliica causes acrodermatitis chroncia atrophicans, a rare skin condition.[2]

Humans are usually infected by nymphs or adults of the B burgdorferi virus, which is carried by ticks. The long, spiral shape of the gram-negative bacteria B. burgdorferi is similar to that of spirochetes. Its width is between 0.2 and 0.5 μm, and its length is between 10 and 30 μm. It has a linear chromosome and varying numbers of linear and circular plasmids. The group B. burgdorferi sensu lato contains at least 20 genospecies. The three genospecies most commonly associated with human diseases are B. burgdorferi sensu stricto, found in North America and Europe, B. afzelii, and B. garinii, found in Europe and Asia. It has been demonstrated that other genospecies in Europe can sometimes, if not always, cause human illness (e.g., B.spielmanii and B.valaisiana.[3]

They are likely to be overlooked because they are so tiny—roughly the size of a poppy seed.[4] It is a type of zoonosis in which animals act as reservoir hosts for the bacteria, and ticks are the primary vector.[5]

Although they are considered "end hosts," humans can contract the infection if they are bitten. Ticks resemble tiny spiders and are classified as arachnids rather than insects. They can be carried indoors on pets or clothing and thrive in the kind of humid environments found in woodlands, moors, and some urban parks and gardens. The most prevalent vector-borne illness in the northern hemisphere is Lyme disease, which is currently endemic in the United Kingdom. Antibiotics should be used for treatment, and the diagnosis should be clinical with test results if feasible.[4]

A brief course of oral antibiotic therapy can cure nearly all patients with early-stage Lyme disease. However, disease in its early stages is not always recognized or clinically evident. The majority of patients with late-stage disease can also benefit from antibiotic therapy; however, a small percentage have antibiotic-refractory Lyme arthritis, necessitating alternative management techniques.[3]

Patients who receive treatment within the first four to six months after being diagnosed have a better prognosis than those who receive treatment later. Untreated Lyme disease can cause a multi-system disorder that affects the heart, joints, nervous system, and eyes. Many times, tick bites go unreported. Adult tick bites typically happen on the lower body, like the groin or lower leg. Bites in children typically occur on the head, neck, and upper body, especially near the hairline. Although there are roughly 1000 laboratory-confirmed cases of Lyme disease in England and Wales each year, the actual prevalence and scope of the issue are unknown. According to a recent study conducted in Norway, there are more than 22 times as many cases of early Lyme disease when the lab-confirmed rate is contrasted with the clinical diagnosis of erythema migrans rash in primary care. This high number might be partially attributed to Norwegian general practitioners' awareness of Lyme disease and their ability to identify the erythema migrans rash. In the USA, the rate increased tenfold when the Centers for Disease Control and Prevention (CDC) surveyed clinical laboratories and included medical claims. Therefore, the PHE website's estimate of 2-3000 cases seems speculative. Men and women are equally impacted, and those between the ages of 45 and 65 seem to be more vulnerable. The majority of cases are According to reports from Southern counties and Scotland, "Lyme disease is the most common

vector-borne disease in the northern hemisphere and is now considered endemic in the UK," with approximately 15% of cases most likely contracted overseas. Europe has a higher prevalence of Lyme disease, with eastern nations like Slovenia, Austria, and Poland having the highest incidence. Some people, like foresters, gamekeepers, walkers, and mountain bikers, are more susceptible to tick bites due to their jobs and outdoor activities. Although there is little chance of getting Lyme disease from a single tick bite, an infected tick can spread the infection with just one bite.[4]

Some areas of Nova Scotia, southeastern Quebec, southern Ontario from the Thousand Islands through the areas on the north shore of Lake Ontario and Lake Erie, southeastern Manitoba, the Lower Mainland of British Columbia, the Fraser Valley, and Vancouver Island are now home to black-legged tick populations. Although this hard-bodied tick's range is currently restricted in Canada, migratory wildlife species, such as birds and deer, are bringing established populations into other parts of southern Canada, and global warming may hasten this spread. Although it is uncommon in Canada, this tick can also spread anaplasmosis and babesiosis in the US.[6]

Early and early disseminated Lyme borre liosis are treated with antibiotics, specifically doxycycline. While ceftriaxone is advised for late neurologic manifestations of Lyme borreliosis, doxycycline can also be used to treat late-stage Lymearthritis.[7]

A member of the tetracycline family, doxycycline is a semisynthetic antibiotic with a wide range of antimicrobial activity. Because they prevent the synthesis of bacterial proteins, all tetracyclines have bacteriostatic properties. By blocking the amino-acyl tRNA from attaching to the acceptor site on the mRNA-ribosome complex, protein synthesis is inhibited at the ribosome.[8]

Tetracyclines have been demonstrated to reduce host-cell inflammatory responses in a number of situations in recent years. In animal models of cerebral ischemia, doxycycline and minocycline, another tetracycline, have been shown to have neuroprotective effects. Furthermore, minocycline was demonstrated to be helpful in animal models of spinal cord injury, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease. It was demonstrated that the tetracyclines' positive effects were linked to a decrease in microglial activation and proliferation as well as the inhibition of interleukin (IL) and inducible nitric oxide synthase. It has been demonstrated that tetracyclines reduce inflammation in Lyme disease by blocking the p38 mitogen-activated protein kinase (MAPK) and NF-B pathways, which are crucial for regulating the production of proinflammatory mediators. Furthermore, by inhibiting caspase-1 and-3 activity, these antibiotics may increase the survival of cells in the central nervous system (CNS). Tetracyclines may therefore inhibit a number of mechanisms that mediate inflammation and cell death. In the current study, we postulated that tetracyclines could regulate the inflammatory responses triggered by B. burgdorferi spirochetes, their lipoproteins, and/or the bacterial debris remaining in the tissues following bacterial death, in addition to their antimicrobial properties. Through in vitro experiments employing peripheral and central nervous system cells involved in the innate immune response, we assessed this hypothesis. The human monocytic cell line THP-1 was used to model systemic effects, and primary cultures of rhesus monkey brain astrocytes and microglia were used to model effects in the central nervous system.[9]

TRANSSMISSION

The two main tick species that spread Lyme disease (LD) in the US are Ixodes scapularis, also known as the black-legged tick, and Ixodes pacificus, also known as the deer tick. The northeastern and mid-Atlantic parts of the United

States, which stretch from Virginia to Maine, as well as the north-central states, especially Wisconsin and Minnesota, and the West Coast, particularly northern California, are where these ticks are most frequently found. Due to their small size and ease of attachment to difficult-to-reach places on the human body, these ticks are challenging to identify. Ticks are most active during the cooler months and are roughly the size of a sesame seed. . Nymphs, on the other hand, are most active in the spring and summer and are about the size of a poppy seed. It can be difficult to detect a tick bite because of these ticks' small size and propensity to adhere to places like the armpits, groin, and scalp. Because nymphs are smaller and more likely to feed on humans, the nymph stage is the most crucial in the spread of Lyme disease. In addition to being more prevalent than adult ticks, nymphal ticks are also more active in the spring and early summer. A human may contract Borrelia burgdorferi if a nymph bites them in order to feed. The bacteria can spread to the host within 36 to 48 hours of feeding, and they are found in the saliva of the tick. Although adult ticks, which usually feed on larger animals like deer, can also spread Lyme disease, humans are less likely to contract the illness from their bites because of their larger size and slower feeding rates.[10]

TRASSMISSION PROCESS

When an infected tick bites a host, it secretes saliva that contains anticoagulants to stop clotting, which is how Lyme disease is spread. From the tick's stomach, the Borrelia bacteria travel to its salivary glands and then enter the bloodstream of the host. The tick must stay attached for 36–48 hours in order for transmission to take place. Tick populations are influenced by environmental factors like habitat and climate, with warmer temperatures extending their range. The bacteria are carried by reservoir hosts such as white-footed mice, and the tick population is maintained by deer. Urbanization and hiking are two examples of human activities that raise the risk of tick exposure. Wear protective clothes, check for ticks, and get rid of them right away to lower the risk.[11,12,13,14,15,16]

The majority of tick bites do not cause infection; only 2-3% of Ixodes scapularis bites cause Lyme disease. The tick must remain attached for 24 to 48 hours in order to transmit. Borrelia burgdorferi is the main culprit in North America, but Europe has several species (B. afzelii, B. garinii, B. burgdorferi, B. spielmanii, and B. bavariensis), which results in a wider range of clinical symptoms.[17]

Although they have been found in patients, three other species of Borrelia—B. bissettii, B. lusitaniae, and B. valaisiana—are not serious infections. The primary causes of Lyme borreliosis in Europe are B. afzelii and B. garinii, with the former being associated with neurological problems and the latter with skin symptoms. B. burgdorferi is the main cause and most commonly linked to arthritis in North America. Lyme borrelia is spread by ticks like Ixodes ricinus (Europe), Ixodes persulcatus (Asia), and Ixodes scapularis (USA) through their saliva; transmission typically takes place after 36 hours of feeding. Larval ticks are not important vectors, and ticks have a life cycle of two to six years. Although transovarial transmission is uncommon, larvae of the related species Borrelia miyamotoi can occasionally be found.[18,19,20]

CO-TRANSMMISSION

One unique way that vector-borne pathogens spread is by co-feeding, in which infected and uninfected vectors eat near one another on the same host. Given that ticks can remain attached to their hosts for days, this technique is typical of diseases carried by ticks. It does not require systemic host infections; instead, it depends on localized, transient infections at the skin level. On the other hand, systemic transmission allows vectors to acquire diseases over long

periods of time by dispersing the virus throughout the host. For some tick-borne viruses, co-feeding transmission can occur nearly instantly, and its latency period is significantly shorter than that of systemic transmission.[21]

TBEV (tick-borne encephalitis virus) and Thogoto virus were the first to be found to co-feed. Co-feeding ticks were able to spread these viruses without infecting rodent hosts with viraemia. Surprisingly, sterilizing antibodies prevented systemic infection in inoculated animals, demonstrating TBEV co-feeding transmission. This experiment demonstrated that, in contrast to systemic transmission, co-feeding transmission is a unique and independent mode of pathogen transfer.[22]

Co-feeding transmission, which was first discovered in tick-borne viruses, was also found in two types of tick-borne bacteria: spirochaete bacteria from the B. burgdorferi s.l. genospecies complex and intracellular gram-negative bacteria of the Anaplasma genus (formerly Ehrlichia). Interestingly, species-specific differences were observed within the Anaplasma genus, with Anaplasma phagocytophilum exhibiting co-feeding transmission.[23,24]

Co-feeding transmission has been shown for a number of tick-borne diseases, such as bacteria and viruses. The three genospecies most closely linked to human Lyme borreliosis, B. burgdorferi sensu stricto, demonstrated co-feeding transmission within the B. burgdorferi s.l. genospecies complex, which includes pathogens that cause Lyme borreliosis, the most prevalent tick-borne illness in the Northern Hemisphere. On the other hand, systemic transmission of Borrelia spirochaetes is far more effective than co-feeding. For example, systemic transmission from competent hosts such as the white-footed mouse (Peromyscus leucopus) can reach 90% in the North American system involving B. burgdorferi s.s. and Ixodes scapularis ticks, while co-feeding transmission was 20 times lower (5%) and only observed under conditions of unnatural tick infestation.[23,25]

The rates of B. burgdorferi s.s. co-feeding transmission varied from study to study; higher rates were seen when European strains of B. burgdorferi were paired with Ixodes ricinus ticks (32.5–60.9%) or an artificial gerbil host (18–88%). Under realistic tick infestation conditions, co-feeding transmission in the European system involving B. afzelii and I. ricinus varied from 1.6% to 55.3%. Although precise co-feeding transmission rates were not disclosed, 95% of lab mice produced at least one co-infected tick in a study on field-collected I. ricinus ticks (mainly infected with B. afzelii). Rates for Ixodes persulcatus and B. garinii varied from 6.0% to 29.0%.

Co-feeding transmission is frequently more effective in the European system (B. afzelii and I. ricinus) than in the North American system (B. burgdorferi s.s. and I. scapularis), however generalization is difficult due to experimental variations. Since the majority of research uses detection techniques like PCR, which cannot verify whether spirochaetes are alive, the survival of spirochaetes obtained from co-feeding transmission is still unknown. Although their long-term survival and infectivity in natural settings are unknown, the culture of live spirochaetes in a lab setting provides evidence of viable transmission. Although generalization is challenging because of experimental variances, co-feeding transmission is often more successful in the European system (B. afzelii and I. ricinus) than in the North American system (B. burgdorferi s.s. and I. scapularis). The survival of spirochaetes obtained by co-feeding transmission is yet unknown because most research relies on detection methods like PCR, which cannot confirm whether spirochaetes are alive. The culture of living spirochaetes in a laboratory context shows signs of viable transmission, despite the fact that their long-term survival and infectivity in wild settings are unclear.[25,26,27, 28, 29]

By moulting and becoming Borrelia-infected nymphs, infected larvae are able to maintain their infection through ransstadial maintenance. Spirochaetes can be acquired by larval ticks through co-feeding (nymph-to-larva) or systemic transmission (host-to-larva). Co-feeding transmission between nymphs is far less frequent and has little bearing on pathogen fitness. Nymph-to-larva co-feeding was 30 times more common than nymph-to-nymph transmission in a study of rodents conducted in Slovakia. It was once thought that B. burgdorferi s.l. caused transovarial transmission, in which infected females transmit spirochaetes to their progeny. However, new research indicates that these reports may have been confused with those of Borrelia miyamotoi, a member of the relapsing fever group. Transovarial transmission in B. burgdorferi s.l. is now thought to be nonexistent.

For B. burgdorferi s.l. pathogens, the quantity of infected larvae generated through systemic transmission and co-feeding are the two main fitness factors.[26,27]



Fig. 1.

Causative organisms

Only three species—Borrelia burgdorferi, B. garinii, and B. afzelii—cause Lyme disease out of the more than a dozen species in the Borrelia burgdorferi sensu lato group. All three species infect Europe, but B. burgdorferi is the only agent in North America.[28] The B. burgdorferi transmission vector in Asia is unknown.[29]

The main way that these bacteria are spread is by Ixodes ticks. Spirochetes are transferred to different hosts when the tick molts into its nymphal stage, where they are obtained by blood feeding by the larva. Because they facilitate host adherence and immune response evasion, plasmid-encoded lipoproteins, such as outer-surface proteins (Osp) and VIsE, are crucial for Borrelia survival. but they come alive during feeding when blood stimulates the production of OspC. This allows them to bypass the host's innate and acquired immunity and reach the tick's salivary gland.[30,31,32]

The three phases of tick development—larval, nymphal, and adult—all depend on blood meals to survive.[33] During subsequent feedings, larvae and nymphs pick up Borrelia from reservoir hosts such as rats and birds. As dead-end hosts, humans contract the disease when bitten by spirochetal nymphal ticks, which are less frequently adults. B. burgdorferi is spread by I. scapularis in the United States and by I. pacificus in the West, where wood rats act as reservoirs for the bacteria.[34,35]

Fig. 2.

The following are the most often causative species:

Borrelia burgdorferi

The main agent in North America, Borrelia burgdorferi, uses special surface proteins (Osps), including OspC, to adapt to tick vectors (Ixodes) and mammalian hosts.[35]

Borrelia afzelii

Common in Europe and Asia, Borrelia afzelii frequently results in skin-related symptoms, such as erythema migrans (EM).[35]

Borrelia garinii

Europe and Asia are home to the more neurotropic Borrelia garinii, which is commonly associated with neurological symptoms such Lyme neuroborreliosis.[35]

CLINICAL ASPECTS OF LYME DISEASE

CONDITION	Signs and symptoms	Additional information
Lyme neuroborreliosis	**Adults:** Bannwarth's syndrome Radiculitis Cranial neuritis (most commonly facial nerve) Meningitis Peripheral neuropathy **Children:** Facial palsy Meningitis	Early to late complication of the disease (weeks to months after infection) 15-25% UK cases (Smith et al, 2000; Lovett et al, 2008)
Lyme arthritis	Mono-articular/oligo-articular arthritis Asymmetrical Usually affects large joints, e.g. the knee	A late complication of the disease (months to years after infection) Uncommon in Europe Associated with *Borrelia burgdorferi*
Lyme carditis	Heart block Typically second degree May progress to complete heart block	Early complication Uncommon Potentially life-threatening May require temporary pacing
Acrodermatitis chronicum atrophicans (ACA)	Chronic skin infection Extensor surfaces of feet and hands Redness and thinning of skin Cigarette paper' appearance Usually seen in older women More common in Eastern Europe	Late complication Uncommon Skin biopsy and PCR may assist diagnosis Associated with *Borrelia afzelii*
Borrelial lymphocytoma	Chronic skin infection Often involves earlobe or nipple Bluish solitary nodule More common in children	Rare form of early localised Lyme disease
Ophthalmic complications	Conjunctivitis Uveitis Keratitis	Uncommon

DIGNOSIS

Laboratory Tests

Direct method

Just 50% of patients with early-stage Lyme disease test positive for the host antibody response to Borrelia burgdorferi infection, and this response takes time to develop. After the commencement of erythema migrans, IgM and IgG antibodies appear 2-4 and 4-6 weeks later, respectively, peaking at 6-8 weeks. While IgG is still detectable at low levels even after successful therapy, IgM drastically decreases after 4–6 months. The patient's epidemiologic history should be taken into consideration when interpreting serologic data.[36]

Because spirochetes are so rare, it is difficult to directly detect Borrelia burgdorferi in clinical samples. The two main direct procedures for diagnosis are PCR and culture, albeit they are not required.[37,38]

Although they need specific knowledge and meticulous controls, methods including immunofluorescence tests, Warthin-Starry and Dieterle silver stains, and microscopy are nonetheless challenging to interpret. Antigen assays are not suggested, with techniques like OspA detection in cerebrospinal fluid and urine antigen detection proving unreliable.[39,40,41]

CULTURE

Because of its limited sensitivity, lengthy incubation period, and requirement for specific medium and knowledge, culture is not frequently employed in clinical practice to diagnose Lyme disease. Nonetheless, it continues to be the gold standard for investigation and diagnosis verification. Wider use might be made possible by increasing sensitivity and streamlining the process. Complex media, including modified Kelly-Pettenkofer (MKP) or Barbour-Stoenner-Kelly (BSK) variants, are necessary for the culture of B. burgdorferi. PCR testing on aliquots is used to increase sensitivity when analyzing cultures using dark-field or fluorescence microscopy (with acridine orange staining).[42]

Because Borrelia burgdorferi reproduces slowly, cultures must be kept for 8–12 weeks before they can be deemed negative.[43,44,5]

PCR

Although the sensitivity of PCR techniques for identifying Borrelia burgdorferi DNA in skin or blood samples is comparable to that of culture, the methodology and gene targets used can affect the results. Because of the reduced sample quantities, PCR is less sensitive for plasma samples. Electrospray ionization mass spectrometry combined with broad-range PCR exhibits promise. With DNA detected in 70–85% of cases, PCR tests are currently primarily employed to assess synovial fluid in patients with Lyme arthritis. Nevertheless, a current infection is not necessarily indicated by a positive PCR result. In the early stages of neuroborreliosis, sensitivity for cerebrospinal fluid samples is low (10–30%), and it is significantly lower in the later stages of the disease.[44,45]

INDIRECT METHODS

The detection of the host's antibody response to Borrelia burgdorferi is one of the indirect ways used to diagnose Lyme disease. The only methods of diagnosing Lyme disease that have FDA approval are antibody-based testing, such serologic assays. However, given that 3.4 million serologic tests are conducted in the United States each year—much more than the estimated 300,000 cases—misuse of these tests is a worry.[46]

INTRATHECAL ANTIBODY PRODUCTION

In Europe, intrathecal antibody production is the gold standard for diagnosing Lyme neuroborreliosis, and both serum and cerebrospinal fluid (CSF) analysis are used to identify the selective production of anti-B. burgdorferi antibodies in the central nervous system. However, the lack of a clear gold standard and variables like different case definitions, assays, and labs make it difficult to interpret results. In acute cases, intrathecal antibody production has a sensitivity of roughly 50% and may continue after treatment. Research indicates that positive outcomes are less frequent in patients with neuroborreliosis in the United States.[47,48,49]

CXCL13

Although its diagnostic utility is still unknown, CXCL13, a B lymphocyte chemoattractant chemokine, is elevated in the cerebrospinal fluid of patients with acute Lyme neuroborreliosis and may be useful in specific clinical contexts. The clinician does not currently have regular access to this test.[50,51]

Other test

Lyme disease should not be diagnosed using cell proliferation assays, ELISPOT assays, cytokine measurements, complement split products, or lymphocyte transformation tests because their clinical utility has not been established. Measurements of natural killer cells (CD57) are useless100. Manuscript by Author Author Manuscript by Author Author Future research will determine the clinical applicability of xenodiagnosis, an experimental test that uses the natural tick vector (Ixodes scapularis) to find signs of infection in Lyme disease. Xenodiagnosis can provide researchers with a tool to create new tests for the disease, even though it is unlikely to be used in routine practice.[52]

TREATMENT

Clinical symptoms	Adults	Children
Early localized Erythema migrans	Doxycycline, 100 mg orally twice per day Amoxicillin, 500 mg orally three times per day Cefuroxime axetil (Ceftin), 500 mg orally twice per day Azithromycin (Zithromax), 500 mg orally once per day	Doxycycline, 4 mg per kg orally per day in two divided doses (maximum of 100 mg twice per day) in children eight years or older Amoxicillin, 50 mg per kg orally per day in three divided doses (maximum of 500 mg per dose) Cefuroxime axetil, 30 mg per kg orally per day in two divided doses (maximum of 500 mg per dose)
Early disseminated Cardiac (atrioventricular block or myopericarditis) or Neurologic (lymphocytic meningitis, facial nerve palsy, and/or encephalitis)	Ceftriaxone (Rocephin), 2 gintravenously per day Or efotaxime (Claforan), 2 gintravenously every eight hours or Doxycycline, 200 to 400 mg orally in two divided doses per day	Ceftriaxone, 50 to 75 mg per kg intravenously per day (maximum of 2 g per dose) Cefotaxime, 150 to 200 mg per kg intravenously per day in three or four divided doses (maximum of 6 g per day) Doxycycline, 4 to 8 mg per kg intravenously in two divided doses per day in children eight years or older (maximum of 100 to 200 mg per dose)
Late Arthritis (without neurologic involvement) Neurologic (encephalitis, encephalomyelitis, meningitis, or peripheral neuropathy) with or without arthritis	Same oral antibiotics as used for erythema migrans Same intravenous antibiotics as used for neurologic symptoms of early disseminated disease	Same oral antibiotics as used for erythema migrans Same intravenous antibiotics as used for neurologic symptoms of early disseminated disease

Immunotherapy Approaches for the Management of Lyme Disease

Since antibiotics are very effective in the early stages of infection, they are typically used to treat Lyme disease, which is caused by Borrelia burgdorferi. However, more sophisticated treatment options are required when Lyme disease advances to late-stage manifestations like Post-Treatment Lyme Disease Syndrome (PTLDS), neurological complications (neuroborreliosis), or chronic arthritis. In the treatment of Lyme disease, immunotherapy—which entails altering or boosting the immune response—has shown promise as a supplement to antibiotics, especially when traditional therapies are not enough. This section describes various immunotherapy strategies, such as monoclonal antibodies, immune modulation, and vaccines, that are being researched for the treatment of Lyme disease.[53,54]

Targeting *Borrelia burgdorferi*

One strategy is to create monoclonal antibodies that can specifically target Borrelia spirochetes, preventing them from infecting host cells or assisting the immune system in eliminating them. For instance, in studies, antibodies that attach to B. burgdorferi's outer surface proteins, such as OspA and OspC, have shown promise. By neutralizing the pathogen or preventing its adherence to host tissues, these antibodies may help stop infection or lower the bacterial load.[55]

Targeting Immune Pathways

Monoclonal antibodies are another strategy that focuses on immune pathways implicated in the inflammatory response that occurs during Lyme disease. For instance, in conditions where inflammation is a major factor, the application of monoclonal antibodies that target the pro-inflammatory cytokine TNF-alpha has been investigated. Targeted antibodies that modulate the immune response may lessen the persistence of symptoms in the later stages of Lyme disease, which frequently involves chronic inflammation, particularly in Lyme arthritis. To fully understand their safety and effectiveness, more research is required as the use of these antibodies in Lyme disease has not yet gained widespread acceptanilace.[56]

Immune modulation and cytokinine blockade

There are both pathogenic and protective components to the immune response in Lyme disease. Evidence of dysregulated immune responses, including persistent inflammation even after the pathogen has been cleared, has been found in certain patients, especially those with PTLDS. Chronic symptoms like fatigue, musculoskeletal pain, and cognitive dysfunction may be exacerbated by this. To enhance results in these situations, immunomodulatory treatments that control the immune response are being investigated.[57]

Interleukin-6 (IL-6) Inhibition

IL-6 is a cytokine that contributes to both chronic inflammation and the acute phase response to infection. Elevated IL-6 levels are seen in certain Lyme disease cases, especially in patients with chronic Lyme arthritis. The use of monoclonal antibodies like tocilizumab to block IL-6 has been studied in Other Cytokine Blockade: The chronic symptoms of Lyme disease may be influenced by pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-17 in addition to IL-6. Lyme disease may benefit from immunotherapies that target these cytokines, which are being researched for a number of inflammatory and autoimmune conditions.[58,59]

Development of Vaccines

In areas where Lyme disease is endemic, a vaccine could be a crucial preventive measure. The U.S. FDA approved a vaccine (Lymerix) in the late 1990s, but it was taken off the market because of side effect concerns and low demand. Since then, fresh initiatives have been made to create vaccines that are safer and more efficient.

OspA-based Vaccines: The outer surface protein A (OspA) of B. burgdorferi, which is essential to the bacteria's capacity to survive inside the tick, was the target of the previous vaccine (Lymerix). However, the vaccine was withdrawn due to worries about autoimmune reactions. Currently, scientists are developing vaccines that target additional immune system components or outer surface proteins that may offer long-term protection without having negative side effects. Vaccines of the Next Generation: Novel vaccine candidates are being developed, such as those that target distinct Borrelia antigens or that stop the tick from spreading the infection. The goal of these vaccines is to elicit a robust immune response that guards against the infection and theinflammatory reactions that cause long-term illness.[60,61]

DISSCUSSION

1. **Antibiotic Therapy**
   - Especially in the early stages of Lyme disease, antibiotics continue to be the mainstay of treatment. Among the frequently used antibiotics are cefuroxime, amoxicillin, and doxycycline. These work well to eradicate the disease-causing Borrelia burgdorferi bacteria
   - The effectiveness of various antibiotics and their combinations has been investigated in recent research. Ceftriaxone, for example, has demonstrated promise in the treatment of chronic Lyme disease symptoms, especially in post-treatment Lyme disease syndrome (PTLDS) cases.

2. **Immunotherapy**
   - One new area in the treatment of Lyme disease is immunotherapy. Its main goal is to alter the immune system in order to better fight the infection.
   - One example of immunotherapy advancements is the creation of vaccines that specifically target Borrelia burgdorferi. By stimulating a strong immune response, these vaccines seek to prevent infection.
   - Additionally, monoclonal antibodies are being researched as a possible therapeutic option. By neutralizing the bacteria or its toxins, these antibodies can lessen the severity of the illness.
   - Furthermore, immunomodulatory treatments are being investigated to treat the autoimmune-like symptoms that certain Lyme disease patients experience. These treatments seek to reduce chronic inflammation and reestablish immunological balance.

RESULTS

In summary, improvements in immunotherapy and antibiotic management strategies for Lyme disease mark a substantial advancement in combating the infection and its aftereffects. Antibiotic therapy is still the mainstay of care, but in order to overcome issues like resistance and lingering symptoms, more research is needed to maximize its effectiveness. With advancements like vaccines, monoclonal antibodies, and immune-modulating medications having the potential to completely transform healthcare, immunotherapy presents a promising supplemental approach. Combining these strategies with personalized medicine could result in more individualized and efficient treatments. But

the path forward calls for ongoing clinical research, interdisciplinary cooperation, and fair access to new treatments. To enhance patient outcomes and fully address the complexities of Lyme disease, these initiatives will be crucial.

REFERENCES

1. Amit Sharma, Bharat Parashar, Esha Vatsa, Shilpa Chandel and Surbhi Sharma "Phyto chemical screening and Anthelmintic activity of leaves of Cedrus deodara (Roxb.)" World journal of pharmacy and pharmaceutical sciences (WJPPS), 2016; 5(8): 1618-1628.
2. Neeru, Shilpi Kashyap, Esha Vatsa, Jitendra Singh and Ankush Sundriyal "Determination of Total Phenolic Content, Total flavonoid Content and Total Antioxidant capacity of different extracts of Roylea elegans Wall. (aerial parts)" World journal of pharmacy and pharmaceutical sciences (WJPPS), 2016; 5(6): 1884-1891.
3. Neeru, Esha Vatsa, Jitendra Singh and Ankush Sundriyal "Pharmacognostic Standardization Parameters of Roylea elegans Wall. (Aerial Parts)" International Journal for Pharmaceutical Research Scholars (IJPRS), 2016; 5(2): 133-140.
4. Amit Sharma, Surbhi Sharma, Shilpa Chandel, Esha Vatsa and Dr. Bharat Parashar "A review on Morchella esculanta: Therapeutically Potent plant" World journal of pharmacy and pharmaceutical sciences (WJPPS), 2016; 5(9): 685- 699.
5. Divya Negi Rawat, Anjali Bisht, Esha Vatsa, Deepika Chandra, Nidhi Chaudhary, Ashok Kumar "Urinary bacterial profile and antibiotic susceptibility pattern among patients of urinary tract infections" High Technology letters, 2023; 29(10): 115-128.
6. Mehak Aggarwal, Ujjwal Nautiyal, Harmeet Singh, Esha Vatsa, Nidhi Chaudhary, Anjali Bisht, Divya Negi "Development and evaluation of drug delivery system containing luliconazole" High Technology letters, 2023; 29(11): 633-652.
7. Jagriti Gairola, Prashant Kukreti, Anjali Bisht, Divya Negi, Nidhi Chaudhary, Esha Vatsa "Development of Chronotherapeutic Delivery System for the Oral Administration of Aceclofenac for Rheumatoid Arthritis by Using Different Polymers" Journal of Chemical Health Risks, 2023; 13(6): 1180-1192.
8. Krati, Dr. Martolia Jaya, et. al, A comprehensive review on in-vitro methods for anti- microbial activity, IP International Journal of Comprehensive and Advanced Pharmacology, 2024; 9(3).
9. Kundan Singh Bora and Esha Vatsa "Pharmacognostic Evaluation of Dendrobium macraei Lindl." Universities Journal of Phytochemistry and Ayurvedic Heights (UJPAH), 2016; 1(20): 29-36.
10. Esha Vatsa and Kundan Singh Bora "Memory Enhancing Activity of Dendrobium macraei Lindl. in Swiss Albino Mice" British Journal of Pharmaceutical Research (BJPR), 2016; 13(2):1-11.
11. Vatsa Esha, Chandel Shilpa, Parashar Bharat, Neeru "Physico-Chemical and Phytochemical Evaluation of Dendrobium macraei Lindl. (Whole Plant)" International Journal of Pharmacognosy and Phytochemical Research (IJPPR), 2016; 8(11): 1801- 1811.
12. Esha Vatsa, Mehak Aggarwal, Shipra Gautam "Formulation and Evaluation of Polyherbal Facial Scrub" Just Agriculture multidisciplinary e-Newsletter, Article ID: 023, 2021; 1(9): 1-6.
13. Shipra Gautam, Madhubala Thakur, Mehak Aggarwal, Esha Vatsa"Azadirachta indica- A Review as a Potent Anti-Diabetic drug" Just Agriculture multidisciplinary e-Newsletter, Article ID:98, 2021; 1(10): 1-6.
14. Esha Vatsa, Samriti Faujdar, Nidhi Sharma, Shilpa Chandel, Mehak Aggarwal"Dendrobium macraei Lindl.: A review on medicinally potent orchid on the basis of recent evidences" Chinese Journal of Medical Genetics, 2022; 31(3): 560-571.

15. Krati, Babita Rawat, Abhishek Bhardwaj, Amandeep Singh, A Comprehensive Review on Indian Barnyard Millet (Echinochloa frumentacea), International Journal of Pharmaceutical Technology and Biotechnology, 2025; 12(1): 01-07
16. Krati, Dr. Martolia Jaya, et. al, A Comprehensive review on in-vitro methods for antimicrobial activity" Educational administration: Theory and Practice" , 2024; 30(6): 8 (2977-2984).
17. Esha Vatsa, Dr. Samriti Faujdar, Shilpa Chandel, Nidhi Chaudhary, Ashok Kumar, Neeru, "Studies on anti-inflammatory activities of whole plant of Dendrobium macraei Lindl." European Chemical Bulletin, 2023; 12(Special Issue 1): 657-664.
18. Esha Vatsa, Dr. Samriti Faujdar, Nitin Kumar, Nidhi Chaudhary, Shilpa Chandel, Neeru, Mehak Aggarwal "Current studies to justify the medicinal potential of the orchid Dendrobium macraei Lindl." European Chemical Bulletin, 2023; 12(S3): 5822-5830.
19. Nidhi Chaudhary, Dr. Deepak Nanda, Dr. Esha Vatsa, Mithilesh Kesari, Harshita Chandra, Simran Singh Rathore "The Promise of Usefulness of the Evergreen Shrub Cassia auriculata" Journal of Advanced Zoology, 2023; 44(4): 1249-1261.
20. Ms Pooja Yadav, Dr. Esha Vatsa, Dr Arti Rauthan, "Enhancing Menstrual Awareness among Adolescent Girls: Evaluating the Influence of School Initiatives" Journal of Chemical Health Risks, 2024; 14(02): 3141-3149.
21. Mehak Aggarwal, Esha Vatsa, Nidhi Chaudhary, Shilpa Chandel, Shipra Gautam, "Formulation and Evaluation of Polyherbal Face Pack" Research Journal of Pharmacy and Technology, 2024; 17(6): 2481-2485.
22. Esha Vatsa, Mehak Aggarwal, Nidhi Chaudhary, Shipra Gautam, Neeru, Nitin Kumar, "Comparison Based on Pharmacognostical and Pharmacological Profile of Thuja Orientalis Linn. And Thuja Occidentalis Linn.: A Review" Naturalista Campano, 2024; 28(1): 3208-3219.
23. Priya Pandey, Esha Vatsa, Gaurav Lakhchora, Md Shamsher Alam, Niyaz Ahamad Ansari, Mohammad Dabeer Ahamad, Sarafarz Ahamad, Mukul Singh, Nitin kumar, "Nano Medicine Advancements in Addressing Rare Neurological Disorders: A Focus on Globoid Cell Leukodystrophy (Krabbe's Disease) Treatment" African Journal of Biological Sciences, 2024; 6(3): 2654-2684.
24. Esha Vatsa, Nidhi Chaudhary, Priya Khadwal, Mehak Aggarwal, Tanya Aggarwal, and Nishant Bhardwaj, "In vitro Antidiabetic Effect and Phytochemical Screening of Cassia biflora Mill." Indian Journal of Natural Sciences, 2025; 15(88): 87726-87733.
25. Anil Kumar, Dr. Esha Vatsa, "AI-Powered Embryo Selection is revolutionized: A Review" South Eastern European Journal of Public Health, 2025; XXVI (1): 6223-6230.
26. Lohani, V., A R, A., Kundu, S., Akhter, M. Q., & Bag, S. Single-Cell Proteomics with Spatial Attributes: Tools and Techniques. ACS omega, 2023; 8(20): 17499–17510. https://doi.org/10.1021/acsomega.3c00795.
27. Amandeep Singh, Deepak Nanda, Ashok Kumar and Abhishek Bhardwaj . In vitro evaluation of anti-inflammatory activity of ageratum conyzoides leaves by Human Red Blood Cell (HRBC) membrane stabilization method, International Journal of Research in Pharmaceutical and Nano Sciences, 2023; 12(6): 196-202.
28. Amandeep Singh, Deepak Nanda, Ashok Kumar, Abhishek Bhardwaj. In vitro evaluation of anti-inflammatory activity of ageratum conyzoides leaves by Human Red Blood Cell (HRBC) membrane stabilization method, International Journal of Research in Pharmaceutical and Nano Sciences, 2023; 12(6): 196-202.

29. Singh A, Nanda D, Bhardwaj A, Kumar A. A pharmacological investigation for therapeutic potential of Callistemon citrinus as an anthelmintic agent (Bottle-Brush Plant). IP Int J Comprehensive Adv Pharmacol, 2024; 9(3): 206-210.
30. Yogesh Tiwari, Amandeep Singh, Bhupendra Kumar, Ashok Kumar. "In Vitro Evaluation of Alpha Amylase Activity of Bark Extracts of Ficus Auriculata". International Journal of Innovative Science and Research Technology. December, 2017; 2(12): 88-92.
31. Bhupendra Kumar, Amandeep Singh, Yogesh Tiwari, Ashok Kumar. UV PROTECTIVE ACTIVITY OF GLYCINE MAX SEEDS. Indian Research Journal of Pharmacy and Science, 2017; 15: 1190-1195.
32. Reena Bhatt, Ashok Kumar, Ankita Sharma. FORMULATION AND EVALUATION OF SHAMPOO FORMULATED BY GLYCINE MAX SEEDS.Indian Research Journal of Pharmacy and Science, 2017; 15: 1232-1238.
33. Kumar A, Nanda D and Gupta A . "A Prospective Study on the Risk Determinants and Economic Burden ofAdverse Drug Reactions in Tertiary Care Hospital". Indian Journal of Natural Sciences, 2025; 15(88): 87957-87961.
34. Ashok Kumar, Deepak Nanda and Abhishek Gupta A holistic approach to adverse drug reactions in hospitals: Classification, risk factors, assessment and economic evaluation- A review. J. Exp. Zool. India, 2024; 27: 2337-2348. DOI: https://doi.org/10.51470/jez.2024.27.2.2337.
35. Sakshi Garg, Ashok Kumar, Varsha Deva, Preeti Biswas, Harsh Rastogi, Heena Farooqui. Immediate-Release Drug Delivery System, Current Scenario, And Future Perspective-A Narrative Review. Jundishapur Journal of Microbiology, 2022; 15(1): 6509-6519.
36. Ashok Kumar, Deepak Nanda, Abhishek Gupta Pattern of Adverse Drug Reactions and Their Economic Impact on Admitted Patients in Medicine Wards of a Tertiary Care Hospital. Library Progress International, 2024; 44(4): 1120-1139.
37. Alisha Rawat, Meenakshi Sajwan, Yamini Chandola,Nidhi Gaur "Assaultive role of thiamine in coalition with selenium in treatment of liver cancer", Journal of emerging technologies and innovative research, 2022; 9(1); 2349-5162.
38. Ghildiyal, P., Bhatt, A., Chaudhary, N., Narwal, S.,Sehgal, P. "Study of various biochemical parameters on atrazine induced glucose-6-phosphate dehydrogenase deficiency in brain" International Journal of Health Sciences, 2022; 6(S7): 2552-2558.
39. Alok Bhatt, Arun Kumar, Pallavi Ghildiyal, Jyoti Maithani, Nidhi Chaudhary, Manish Nawani, Sonia Narwal "Phytochemical Profile of Melissa parviflora Benth" Neuro Quantology, 2022; 20(9); 2426-2428.
40. Palika Sehgal, Alok Bhatt, Sonia Narwal, Deepak P. Bhagwat, Nidhi Chaudhary et.al Formulation Characterization Optimization and In Vitro Evaluation of Aceclofenac Topical Emulgel, Neuro Quantology, 2022; 20(14): 1-09.
41. Sneha Rawat, Praveen Kumar Ashok, Abhishek bhardwaj "A review on Oro dispersible Tablet of Telmisartan" Org-Journal of Emerging Technologies and Innovative research (JETIR), May 2023; 10(5): i104-i112.
42. Jaison Varghese, Nitin kumar, Sapna Chaudhar, Abhishek Bhardwaj(2024) "Comparative In-Vitro Antioxidant and Antimicrobial Potential of Some Medicinal Plants"African Journal of Biological Sciences, https://doi.org/10.48047/AFJBS.6.Si3.2024.3340-3346.

43. Asima Imtiyaz, Ajay Singh, Abhishek Bhardwaj(2024) "Green synthesis of iron oxide nanoparticles from Iris kashmiriana (Mazar-Graveyard) Plant Extract its characterization of biological activities and photocatalytic activity" Journal of Industrial and Engineering Chemistry, https://doi.org/10.1016/j.jiec.2024.09.004.
44. Hem Chandra Pant, Bhawana Goswami, Ashok Kumar, Abhishek Bhardwaj, Shanti Rauthan and Amita pandey "A Review Paper on Bacopa monniera and Role of Artificial Intelligence (AI) in Medicinal Plant for Management and Treatment of Various Diseases" Indian Journal of Natural Sciences, 2025; 15(88): 01-10.
45. Vishwajeet Bachhar, Vibha Joshi , Ajay Singh,, M. Amin Mir , Abhishek Bhardwaj(2025)"Antibacterial, Antioxidant, and Antidiabetic Activities of TiO2 Nanoparticles Synthesized Through Ultrasonication Assisted Cold Maceration from Stem Extract of Euphorbia hirta"Nano Bioscience, https://doi.org/10.33263/LIANBS141.001.
46. Nidhi Chaudhary, "A review on: The deciduous shrub "Punica granatum" , European journal of biomedical and pharmaceutical sciences, 2016; 3(7); 2349-2388.
47. Singh Harmeet and Nidhi Chaudhary, "Evaluation of Lakshadi Guggul on experimentally induced global cerebral ischemia/reperfusion injury". World journal of Pharmacy and Pharmaceutical Sciences, 2016; 6(1); ISSN 2278-4357.
48. Nidhi Chaudhary and Harmeet Singh, "Evaluation of Punica Granatum Leaves Extract In Scopolamine Induced Learning And Memory Impairment In Mice". World journal of Pharmacy and Pharmaceutical Sciences, 6(6); 1677-1703.
49. Amandeep Singh, Pankaj Nainwal ,Deepak Nanda ,D.A. Jain, SOLUBILITY ENHENCEMENT OF PIOGLITAZONE WITH COMPLEXATION OF HYDROXYPROPYL-β-CYCLODEXTRIN, Digest Journal of Nanomaterials and Biostructures, Apr 2012; 2(4): p.91-97.
50. Pankaj Nainwal Deepak Nanda, Amandeep Singh, D. A. Jain, QUANTITATIVE SPECTROPHOTOMETRIC DETERMINATION OF DOMPERIDONE TABLET FORMULATIONS USING IBUPROFEN SODIUM AS HYDROTROPIC SOLUBILIZING AGENT, Digest Journal of Nanomaterials and Biostructures, 2012; 2(4): 751 – 753
51. Deepak Nanda, Pankaj Nainwal, Amandeep Singh, D.A.Jain, REVIEW ON MIXED-SOLVENCY CONCEPT: A NOVEL CONCEPT OF SOLUBILIZATION, Deepak Nanda et al. ,Journal of Pharmacy Research, 2012; 3(2): 411-413
52. Pankaj Nainwal, Amandeep Singh, Deepak Nanda, D.A.Jain, NEW QUANTITATIVE ESTIMATION OF ROSUVASTATIN BULK SAMPLE USING SODIUM BENZOATE AS HYDROTROPIC SOLUBILIZING AGENT, Journal of Pharmacy Research, 2012; 3(1): 6-8
53. Nainwal.P, Bhagla.A, Nanda.D, STUDY ON ANTIOXIDANT POTENTIAL AND WOUND HEALING ACTIVITY ON THE AQUEOUS EXTRACT OF FRUITS OF GARCINIA MANGOSTANA, IJPI's Journal of Pharmacognosy and Herbal Formulations, Volume-1
54. Pankaj Nainwal , Kapil Kalra, Deepak Nanda , Amandeep Singh, STUDY OF ANALGESIC AND ANTI-INFLAMMATORY ACTIVITIES OF THE ETHANOLIC EXTRACT ARIAL PARTS OF FUMARIA VAILLANTII LOISEL, Asian Journal of Pharmaceutical and Clinical Research, 2011; 4(1).
55. Amandeep Singh, Pankaj Nainwal , Deepak Nanda, D.A.Jain, SOLUBILITY ENHANCEMENT STUDY OF PIOGLITAZONE USING SOLID DISPERSION AS SOLUBILIZATION TECHNIQUE, International Journal of Science Innovations and Discoveries, Amandeep Singh et al., IJSID, 2011; 1(2): 95—100

56. Amandeep Singh, Pankaj Nainwal , Deepak Nanda, D. A. Jain, THE SOLUBILITY ENHANCEMENT STUDY OF PIOGLITAZONE USING DIFFERENT SOLUBLIZATION TECHNIQUIES, International Journal of Pharmacy & Pharmaceutical Sciences, 2012; 4(2).
57. Deepak Nanda, Pankaj Nainwal, Amandeep Singh, D.A.Jain, SOLUBILITY ENHANCEMENT STUDY OF DOMPERIDONE USING DIFFERENT SOLUBILIZATION TECHNIQUES, International Journal of Pharmacy and Pharmaceutical Sciences, 2012; 2(3).
58. Pankaj Nainwal, Priyanka Sinha, Amandeep Singh, Deepak Nanda, D.A.Jain, A COMPARATIVE SOLUBILITY ENHANCEMENT STUDY OF ROSUVASTATIN USING SOLUBILIZATION TECHNIQUES, International Journal of Applied Biology & Pharmaceutical Technology, Oct - Dec -2011; 2(4).
59. Pankaj Nainwal , Deepak Nanda, Amandeep Singh, D. A. Jain, FORMULATION AND EVALUATION OF SOLID DISPERSION OF ROSUVASTATIN WITH VARIOUS CARRIERS ,Pharmacie Globale International Journal Of Comprehensive Pharmacy, Issn 0976-8157.
60. Pankaj Nainwal, Amandeep Singh1, Deepak Nanda, D.A.Jain, SOLUBILITY ENHANCEMENT OF AN ANTIHYPERLIPIDEMIC DRUG ROSUVASTATIN BY SOLID DISPERSION TECHNIQUE, International Journal of PharmTech Research IJPRIF ISSN : 0974-4304, March-June 2012; 2: 3.
61. Kshitiz Agrawal, Pragati Bailwal, Amandeep Singh. Prem Saini, DEVELOPMENT OF QUALITY STANDARDS OF SUPRABHATAM CHURNA: A POLY HERBAL FORMULATION, International Journal of Pharmaceutical Research & Development,IJPRD, 2011; 4, June 2012.
62. Kapil Kalra, Amandeep Singh, Manisha Gaur, Ravindra P. Singh, and D. A. Jain, ENHANCEMENT OF BIOAVAILABLITY OF RIFAPENTINE BY SOLID DISPERSION TECHNIQUE, International Journal Of Pharmacy & Life Sciences, Kalra et al ., April, 2011; 2(4).
63. Pankaj nainwal ,Ranveer batsa, Amandeep singh, Deepak nanda, MEDICINAL PLANT STUDIES INFLUECED BY THE BIOTECHNOLOGICAL METHODS: A UPDATED REVIEW, International Journal of Pharma and Bio Sciences, Apr-June-2011; 2(2).
64. Amandeep Singh, Sandhiya Pal, Prem Saini, IN- VITRO EVALUTION OF ANTI-INFLAMMATOTRY ACTIVITY OF TERMANALIA ARJUNA BARK EXTRACT, Journal of Innovative trends in Pharmaceutical Sciences,Vol-1(1): 9-12.
65. Amandeep Singh, Pramila Chauhan, Prem Saini, IN-VITRO ANTI-INFLAMMATORY EVALUTION OF HYDROALCOHALIC LEAVES EXTACT OF PINUS ROXBURGHII BY HRBC METHOD, International journal of Research in Pharmaceutical and Nano Sciences, 2013; 2(3): 268-271.
66. Amandeep Singh, Sumit Negi, Prem Saini, In Vitro Anti-Inflammatory Evaluation Of Leaves Using Hydroalcohalic Extract Of “Mangifera indica” International Journal of Pharmacy and Integrated Life Sciences, V1-(I7) PG (93-98).
67. Aman Deep Baghla, Kshitij Agarwal, Ramesh Verma and Deepak Nanda, Wound Healing Effect of the Aqueous Extract of the Leaves of Psidium guajava Linn., International Journal of chemicals and Life Sciences, 2013; 02 (03): 1104-1106.
68. Aman Deep Baghla, Kshitij Agarwal, Ramesh Verma and Deepak Nanda, WOUND HEALING EFFECT OF THE AQUEOUS EXTRACT OF THE LEAVES OF PSIDIUM GUAJAVA LINN., International Journal of chemicals and Life Sciences, 2013; 02(03): 1104-1106.

69. Bhupendra Kumar, Meenakshi Ghildiyal, Yogesh Tiwari , Deepika Chauhan, Amandeep Singh, IN-VITRO ANTI-INFLAMMATORY ACTIVITY OF GLYCINE MAX SEEDS ,Indo American Journal Of Pharmaceutical Sciences, 2018; 05(02): 868-871.
70. Piyali Dey, Jyoti Pandey, Bhupendra kumar, Amandeep Singh, IN VITRO ANTHELMINTIC ACTIVITY OF BARK EXTRACTS OF ARTOCARPUS HETEROPHYLLUS, International Journal of Pharmacy & Pharmaceutical Research, 2018; 03(11): 33-40.
71. Bhupendra Kumar, Yogesh Tiwari, Amandeep Singh, Vineet Kumar, IN VITRO ANTIUROLITHIC ACTIVITY OF FICUS PALMATA LEAVES, International Journal Of Pharmaceutical Technology And Biotechnology, 2019; 6(1): 01-09.
72. Md. Daneyal Khurshid, Vivek Shukla, Bhupendra Kumar and Amandeep A Review Paper on Medicinal Properties of Phyllanthus emblica , International Journal of Pharmacy and Biological Sciences, 2020; 10(3): 102-109.
73. Mr. Dwivedi Vishal, Mrs. Nisha A Bhatt, Dr. Amandeep Singh PREPARATION AND STANDARDIZATION OF NAVKARSHIKA CHURNA, World Journal Of Pharmacy And Pharmaceutical Sciences, 2020; 9(8).
74. Mitun Saha1, Mr. Bhupendra Kumar, Dr. Amandeep Singh Review Article on Various Phytochemicals and Different Medicinal Activities of Haritaki International Journal of Innovative Science and Research Technology, June 2020; 5(6).